Abstract: A charging system of an electric vehicle battery is provided. The charging system has a charging station and at least one charging cable connectable to a battery to be charged. The charging station has at least one power unit provided with a power card adapted to charge the battery and a female-type connector adapted to connect to a male-type connector of the at least one charging cable. The at least one charging cable and the charging station have respective authentication circuits configured to implement a cable authentication algorithm which, in case of positive outcome, enables charging the battery. The charging system allows charging batteries of different types and working voltages. A method for charging an electric vehicle battery is also provided.

Abstract: A charging system of an electric vehicle battery is provided. The charging system has a charging station and at least one charging cable connectable to a battery to be charged. The charging station has at least one power unit provided with a power card adapted to charge the battery and a female-type connector adapted to connect to a male-type connector of the at least one charging cable. The at least one charging cable and the charging station have respective authentication circuits configured to implement a cable authentication algorithm which, in case of positive outcome, enables charging the battery. The charging system allows charging batteries of different types and working voltages. A method for charging an electric vehicle battery is also provided.

Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.

Abstract: The invention relates to a process for preparation of the compound 3-methyl-5-benzyloxy-2-(4-benzyloxyphenyl)-1H-indole 5, an intermediate for the synthesis of bazedoxifene and bazedoxifene acetate.

Abstract: The invention relates to a process for preparation of the compound 3-methyl-5-benzyloxy-2-(4-benzyloxyphenyl)-1H-indole 5, an intermediate for the synthesis of bazedoxifene and bazedoxifene acetate.

Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.

Abstract: Disclosed is a process for the preparation of toltrazuril of formula (I) via the intermediate N-methyl-N?-[3-methyl-4-[4-[(trifluoromethyl)thio]phenoxy]phenyl] imidodicarbonic diamide of formula (III) wherein intermediate (III) is obtained via a novel intermediate without the use of potentially hazardous reagents or potentially unstable intermediates.

Abstract: Disclosed is a process for the preparation of toltrazuril of formula (I) via the intermediate N-methyl-N?-[3-methyl-4-[4-[(trifluoromethyl)thio]phenoxy]phenyl] imidodicarbonic diamide of formula (III) wherein intermediate (III) is obtained via a novel intermediate without the use of potentially hazardous reagents or potentially unstable intermediates.

Abstract: The invention relates to an aqueous composition useful for producing antimicrobic polymer films, comprising at least an anionic silver complex, one or more cationic organic components with microbicidal activity, a solvent and a polymeric component. Said antimicrobic films can be obtained by depositing the aqueous composition of the invention on the surface to be treated, possibly followed by a thermosetting or photocuring treatment. The antimicrobic polymer films can be produced on surfaces of containers made of plastic, glass, ceramic or metallic material, thereby ensuring a barrier effect which protects the treated surface from invasions of external microbial agents borne by the air or hands of workers who use such containers.

Abstract: The present invention generally relates to Titanium dioxide derivatives of formula TiO2-[L]-Ag+, functionalized with silver cations by a bifunctional mercapto alkylsilane ligand. The present derivatives are useful e.g. as antimicrobic, antiseptic and/or antiviral agent, in particular in the form of pharmaceutical compositions for topical use.

Abstract: The present invention generally relates to silver complexes of formula (I) and (II), having high stability and showing antimicrobial activity. The invention also relies on compositions containing said photochemically stable silver complexes of formula (I) and (II), optionally admixed with at least another antimicrobial agent, thus enhancing their antimicrobic activity.

Abstract: The present invention relates to a dioxide silicon or titanium derivative of formula (I): (MO2)?(Am+)y, as active ingredient for the preparation of a composition having antibacterial properties useful, e.g. for topical administration. The dioxide derivatives of the present invention comprises anionic silica (SiO2)n? or anionic titanium dioxide particles (TiO2)n?, adsorbed with at least one cationic pharmaceutical active moiety (Am+), which may include, for instance, known antibacterial agents such as chlorexidine and the like. Furthermore, the invention relates to a composition for topical use, which may form an efficacious barrier against external microbes, substantially avoiding any infection on the affected skin.

Abstract: The present invention describes a process for the synthesis of ursodeoxycholic acid wherein the purification of the crude ursodeoxycholic acid (containing approximately 13-15% of chenodeoxycholic acid impurity) takes place first passing through a salification with imidazole and a subsequent purification via “methyl ester”, which allows a finished product with an extremely low content of known “cheno and “litho” impurities to be obtained. The present invention also describes the recovery steps of cholic acid and 3?-hydroxy-7-ketocholanic acid from the mother liquors of process intermediates.

Abstract: The present invention describes a process for the synthesis of ursodeoxycholic acid wherein the purification of the crude ursodeoxycholic acid (containing approximately 13-15% of chenodeoxycholic acid impurity) takes place first passing through a salification with imidazole and a subsequent purification via “methyl ester”, which allows a finished product with an extremely low content of known “cheno and “litho” impurities to be obtained. The present invention also describes the recovery steps of cholic acid and 3?-hydroxy-7-ketocholanic acid from the mother liquors of process intermediates.

Abstract: The present invention relates, in a first aspect, to a process preparing vilazodone hydrochloride that comprises the reaction of 3-(4-chloro-1-hydroxy-butyl)-1H-indol-5-carbonitrile with 5-piperazin-1-yl-benzofuran-2-carboxylate methyl hydrochloride with the formation of a 1,4-piperazine, with subsequent dehydration, hydrogenation and treatment with ammonia, to obtain vilazodone in free base form that is then converted into the hydrochloride thereof.

Abstract: The present invention relates, in a first aspect, to a process preparing vilazodone hydrochloride that comprises the reaction of 3-(4-chloro-1-hydroxy-butyl)-1H-indol-5-carbonitrile with 5-piperazin-1-yl-benzofuran-2-carboxylate methyl hydrochloride with the formation of a 1,4-piperazine, with subsequent dehydration, hydrogenation and treatment with ammonia, to obtain vilazodone in free base form that is then converted into the hydrochloride thereof.

Abstract: Crystalline polymorphic forms of a compound of formula N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide are described. The two polymorphic forms, named polymorphic Form A and polymorphic Form B, can be used in the treatment of drug addiction and alcoholism and have very good stability. Methods for preparing the polymorphic forms are also described.

Abstract: There is described a process for the preparation of cinacalcet hydrochloride (I) which includes the steps of: a) reacting (R)-(+)-1-(1-naphthyl)ethylamine (II) with 3-[3-(trifluoromethyl)phenyl]propenaldehyde (III) to afford the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[1-(1-naphthyl)ethylamine (IV); b) reducing the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[-1-(1-naphthyl)ethylamine (IV) with a sequential addition of:—a solution of sodium borohydride, methanol and a base,—oxalic acid and—a base to obtain (R)—N-[3-[3-(tifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) by passing through the precipitation of the oxalate salt of compound (V) after the addition of oxalic acid; c) hydrogenating (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) thus obtaining (R)—N-(3-(3-(trifluoromethyl)phenyl]propyl]-1-(1-naphthyl)ethylamine cinacalcet base (VI), which is retaken in ethyl acetate; and d) treati

Abstract: The present invention relates, in a first aspect, to a process preparing vilazodone hydrochloride that comprises the reaction of 3-(4-chloro-1-hydroxy-butyl)-1H-indol-5-carbonitrile with 5-piperazin-1-yl-benzofuran-2-carboxylate methyl hydrochloride with the formation of a 1,4-piperazine, with subsequent dehydration, hydrogenation and treatment with ammonia, to obtain vilazodone in free base form that is then converted into the hydrochloride thereof.

Abstract: Crystalline polymorphic forms of a compound of formula N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide are described. The two polymorphic forms, named polymorphic Form A and polymorphic Form B, can be used in the treatment of drug addiction and alcoholism and have very good stability. Methods for preparing the polymorphic forms are also described.